EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Intravenous IRON therapy outcomes according to iron deficiency type in HEART failure (IRON-HEART)

Emrah Kaya, Emre Berk Erkip, Barış Küçük, Fevzican Doğru, Uğur Güven, Ömer Furtuna, Deniz Arda Barlas, Fatih Kahraman, Mevlüt Demir, Gökhan Sönmez, Halil İbrahim Durmuş, Mehmet Ali Astarcıoğlu und 1 weitere

Frontiers in Cardiovascular Medicine · 19.11.2026 · 13

DOI: 10.3389/fcvm.2026.1944221 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Cardiovascular Medicine, online erschienen am 19.11.2026. Verfasst von Emrah Kaya und 12 weiteren Autor:innen. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Intravenous iron is recommended for heart failure (HF) with iron deficiency. A recent framework describes three mechanistic iron-deficiency phenotypes, but their clinical relevance and the prognostic value of the change in transferrin saturation (ΔTSAT) after intravenous iron are unknown. We examined both in patients treated with ferric carboxymaltose (FCM).

Methods

In this retrospective single-center cohort, 146 patients with chronic HF received a single 1,000 mg dose of FCM and were classified into non-mutually exclusive, study-defined Type 1–3 phenotypes. The primary outcome was a composite of all-cause death, HF hospitalization, or emergency department visit for worsening HF within 1 year. Associations were estimated with logistic regression adjusted for age, sex, left ventricular ejection fraction, NYHA class, and anemia, with sensitivity analyses including Cox regression over the protocol-defined follow-up (to 1 year after the post-treatment TSAT measurement). ΔTSAT analyses were exploratory.

Results

The composite outcome occurred in 32 patients (21.9%). No phenotype was significantly associated with the outcome: Type 1 (adjusted odds ratio [OR] 2.60, 95% confidence interval [CI] 0.84–8.01), Type 2 (OR 0.40, 95% CI 0.11–1.42), and Type 3 (OR 0.66, 95% CI 0.21–2.11); NYHA class III–IV showed a borderline association (OR 3.41, 95% CI 0.95–12.18). Over the longer protocol-defined follow-up (40 events), the hazard ratio for Type 1 was 2.99 (95% CI 1.19–7.51). Among 139 patients with post-treatment TSAT, ΔTSAT was not associated with the outcome (adjusted OR per 10-point increase 1.00, 95% CI 0.80–1.24), with no effect modification by phenotype (global p = 0.37); however, in 22 of 27 patients with an event, the event preceded the post-treatment measurement. Discrimination (area under the receiver operating characteristic curve) was poor for baseline TSAT (0.57), ΔTSAT (0.50), and ferritin (0.44).

Conclusion

Operationally defined phenotypes were not significantly associated with the 1-year composite outcome; marked hypoferremia (Type 1) demonstrated a consistent directional signal across analyses, although estimates were imprecise and require prospective validation. Because most events preceded the post-treatment TSAT measurement, the prognostic value of the TSAT response could not be assessed. The present results should be considered exploratory owing to limited sample size and event rates.

Zitieren

APA

Kaya, E., Erkip, E. B., Küçük, B., Doğru, F., Güven, U., Furtuna, Ö., Barlas, D. A., Kahraman, F., Demir, M., Sönmez, G., Durmuş, H. İ., Astarcıoğlu, M. A., & Şen, T. (2026). Intravenous IRON therapy outcomes according to iron deficiency type in HEART failure (IRON-HEART). Frontiers in Cardiovascular Medicine, 13. https://doi.org/10.3389/fcvm.2026.1944221

Vancouver

Kaya E, Erkip EB, Küçük B, Doğru F, Güven U, Furtuna Ö, et al. Intravenous IRON therapy outcomes according to iron deficiency type in HEART failure (IRON-HEART). Frontiers in Cardiovascular Medicine. 2026;13. doi:10.3389/fcvm.2026.1944221

BibTeX
@article{Kaya2026,
  author = {Kaya, Emrah and Erkip, Emre Berk and Küçük, Barış and Doğru, Fevzican and Güven, Uğur and Furtuna, Ömer and Barlas, Deniz Arda and Kahraman, Fatih and Demir, Mevlüt and Sönmez, Gökhan and Durmuş, Halil İbrahim and Astarcıoğlu, Mehmet Ali and Şen, Taner},
  title = {Intravenous IRON therapy outcomes according to iron deficiency type in HEART failure (IRON-HEART)},
  journal = {Frontiers in Cardiovascular Medicine},
  year = {2026},
  volume = {13},
  doi = {10.3389/fcvm.2026.1944221}
}
Kostenlos starten →